{"id":"fludarabine-plus-cyclophosphamide","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Infection"},{"rate":"40-60","effect":"Nausea and vomiting"},{"rate":"40-50","effect":"Fatigue"},{"rate":"20-40","effect":"Mucositis"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Hemorrhage"},{"rate":"5-10","effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludarabine is a purine analog that inhibits DNA synthesis and repair in lymphoid cells, while cyclophosphamide is an alkylating agent that cross-links DNA strands, causing cell death. Together, they create a synergistic cytotoxic effect against malignant B-lymphocytes in CLL. The combination also provides immunosuppression, which can be beneficial in autoimmune-mediated hematologic conditions.","oneSentence":"Fludarabine and cyclophosphamide work together as a chemotherapy combination that damages cancer cell DNA and suppresses immune function to treat chronic lymphocytic leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:55.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT02830724","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":"Pancreatic Cancer, Renal Cell Cancer, Breast Cancer","enrollment":124},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":"Melanoma","enrollment":170},{"nctId":"NCT07297667","phase":"PHASE1","title":"GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-01","conditions":"Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic","enrollment":86},{"nctId":"NCT06733935","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)","status":"RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2024-11-04","conditions":"Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":144},{"nctId":"NCT06060613","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Obsidian Therapeutics, Inc.","startDate":"2023-10-25","conditions":"Tumor Skin, Metastatic Melanoma, Melanoma","enrollment":208},{"nctId":"NCT07444632","phase":"PHASE1","title":"Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Lymphoid, Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT06834282","phase":"PHASE1","title":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","status":"RECRUITING","sponsor":"CERo Therapeutics Holdings, Inc.","startDate":"2025-04-07","conditions":"AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Acute Lymphoblastic Leukemia, B-All","enrollment":20},{"nctId":"NCT06847269","phase":"PHASE2","title":"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-21","conditions":"Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT05826535","phase":"PHASE1, PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":"Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":270},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT07492628","phase":"PHASE1","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":"Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":42},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT07223021","phase":"PHASE3","title":"A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-20","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":130},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy","enrollment":9},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":"Relapsed/Refractory CD19-positive B-ALL","enrollment":6},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT02133196","phase":"PHASE2","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-23","conditions":"Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC","enrollment":85},{"nctId":"NCT03412877","phase":"PHASE2","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-06","conditions":"Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer","enrollment":285},{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":"SLE (Systemic Lupus)","enrollment":3},{"nctId":"NCT04103879","phase":"PHASE2","title":"US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2020-11-13","conditions":"High Risk Hematological Malignancy, Cord Blood Transplant","enrollment":30},{"nctId":"NCT07487402","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-03-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT07487597","phase":"EARLY_PHASE1","title":"Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors","status":"RECRUITING","sponsor":"TCRCure Biopharma Ltd.","startDate":"2026-02-28","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT07101432","phase":"PHASE1","title":"Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-11-04","conditions":"Head and Neck Cancer","enrollment":33},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06658951","phase":"NA","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","status":"RECRUITING","sponsor":"UTC Therapeutics Inc.","startDate":"2025-04-03","conditions":"HER2-positive Advanced Malignant Solid Tumors","enrollment":30},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT03745326","phase":"PHASE1, PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-16","conditions":"Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer","enrollment":5},{"nctId":"NCT06375993","phase":"PHASE1","title":"A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Adicet Therapeutics","startDate":"2024-11-10","conditions":"Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc)","enrollment":180},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT07480954","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-04","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma","enrollment":36},{"nctId":"NCT07480941","phase":"PHASE1","title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Glioblastoma, High-grade Glioma, Malignant Glioma","enrollment":36},{"nctId":"NCT07479797","phase":"PHASE3","title":"Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-08","conditions":"Relapsed or Refractory Large B-cell Lymphoma (r/r LBCL)","enrollment":550},{"nctId":"NCT02601313","phase":"PHASE2","title":"Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-11-09","conditions":"Relapsed/Refractory Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT03441958","phase":"PHASE1, PHASE2","title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-03-07","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT07480928","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease","enrollment":42},{"nctId":"NCT05092451","phase":"PHASE1, PHASE2","title":"Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-01","conditions":"B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML)","enrollment":80},{"nctId":"NCT06153251","phase":"PHASE1","title":"A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-23","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":187},{"nctId":"NCT06500273","phase":"PHASE2","title":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","status":"RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2024-06-18","conditions":"Large B-cell Lymphoma","enrollment":250},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT07480213","phase":"PHASE1, PHASE2","title":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage","enrollment":60},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT07477912","phase":"PHASE1, PHASE2","title":"Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2025-02-01","conditions":"Multiple Myeloma Refractory","enrollment":30},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":440},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT07015983","phase":"PHASE2","title":"A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-07-14","conditions":"Lupus Erythematosus, Systemic, Lupus Nephritis","enrollment":89},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06865664","phase":"PHASE1","title":"FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-22","conditions":"Rhabdomyosarcoma","enrollment":50},{"nctId":"NCT06026319","phase":"PHASE1","title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-10-26","conditions":"Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07038447","phase":"PHASE1","title":"A Study of KITE-363 in Participants With Refractory Autoimmune Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2025-07-02","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis","enrollment":52},{"nctId":"NCT05478837","phase":"PHASE1","title":"Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-07-20","conditions":"Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":12},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":300},{"nctId":"NCT03590574","phase":"PHASE1, PHASE2","title":"Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma","status":"TERMINATED","sponsor":"Autolus Limited","startDate":"2018-08-30","conditions":"T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT06481735","phase":"PHASE1, PHASE2","title":"TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-02-15","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT06186401","phase":"PHASE1","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","status":"RECRUITING","sponsor":"Hideho Okada, MD, PhD","startDate":"2024-04-30","conditions":"EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma","enrollment":20},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT04579523","phase":"PHASE1","title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06711146","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-12-24","conditions":"Systemic Lupus Erythematosus","enrollment":36},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT05022849","phase":"PHASE1","title":"A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-28","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT07284433","phase":"PHASE1, PHASE2","title":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse","enrollment":178},{"nctId":"NCT07467863","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC","enrollment":48},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT05442515","phase":"PHASE1, PHASE2","title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-28","conditions":"B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia","enrollment":126},{"nctId":"NCT07411599","phase":"PHASE1, PHASE2","title":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-29","conditions":"Colorectal Cancer, Peritoneal Metastases, Carcinomatosis","enrollment":28},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06043323","phase":"PHASE2","title":"A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-08","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT07164469","phase":"PHASE2","title":"Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-28","conditions":"Large B-cell Lymphoma, Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT05993299","phase":"PHASE2","title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2019-12-31","conditions":"Neoplasms","enrollment":7},{"nctId":"NCT06930651","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-03","conditions":"Myeloid Malignancies","enrollment":42},{"nctId":"NCT06066359","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-11-30","conditions":"Myeloma","enrollment":44},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT06185751","phase":"PHASE1","title":"Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-08-22","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT07372885","phase":"PHASE1, PHASE2","title":"GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia","status":"NOT_YET_RECRUITING","sponsor":"University of Manchester","startDate":"2026-02-09","conditions":"Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic","enrollment":50},{"nctId":"NCT06688799","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-11-23","conditions":"Autoimmune Diseases","enrollment":18},{"nctId":"NCT05537766","phase":"PHASE2","title":"Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies","status":"TERMINATED","sponsor":"Kite, A Gilead Company","startDate":"2022-11-01","conditions":"Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma","enrollment":19},{"nctId":"NCT05748197","phase":"PHASE1","title":"A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT07304154","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fludarabine plus Cyclophosphamide","genericName":"Fludarabine plus Cyclophosphamide","companyName":"German CLL Study Group","companyId":"german-cll-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludarabine is a small molecule inhibitor of the enzyme ribonucleoside-diphosphate reductase RR1. It is used in combination with Cyclophosphamide to treat various cancers, including Hepatocellular Carcinoma, Human Papillomavirus-Related Carcinomas, and others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}